SBIO ALPS Medical Breakthroughs ETF
S-Network Medical Breakthroughs TR USD

NAV as of 16-May-2022

26.3983

4 Week: 24.02 - 32.87

52 Week: 24.02 - 50.12

Latest Closing Price

27.43

Premium / Discount

-0.14

Expense Ratio

0.5%

Investment Objective

The investment seeks investment results that correspond (before fees and expenses) generally to the performance of its underlying index, the S-Network® Medical Breakthroughs Index. The fund employs a "passive management" - or indexing - investment approach designed to track the performance of the underlying index. It will normally invest at least 80% of its net assets in securities that comprise the underlying index. The underlying index is comprised of small and mid-cap stocks of biotechnology companies that have one or more drugs in either Phase II or Phase III of the U.S. Food and Drug Administration clinical trials.

Main Fund Characteristics

Fund Manager:
ALPS
Asset Under Management:
98,484,016
Launch Date:
29/12/2014
Asset Class:
Equity
Replication Method:
Physical-Full
Number of Holdings:
132
Trading Currency:
USD
Style:
Small Growth
Region/Sector/Strategy:
N.A / Healthcare / N.A
Exchange:
NYSE

Performance

Period Performance Returns(%) Volatility(%) Risk Adjusted Performance
YTD-38.923.26-11.92
1 Day-5.950.000.00
1 Week7.4210.230.73
1 Month-20.1019.75-1.02
3 Months-23.5827.70-0.85
6 Months-42.8234.62-1.24
1 Year-43.9738.68-1.14
2 Years-38.6350.78-0.76
3 Years-23.1066.26-0.35
5 Years0.9076.630.01
10 Years0.000.000.00

Price History

-

Annual Performance Return

2012201320142015201620172018201920202021
Price (%) 0.00000.00000.000028.0775-27.653944.9849-11.192649.864321.2092-17.5497
Nav (%) 0.00000.00000.00000.00000.00000.00000.00000.00000.00000.0000
Rank 0.00000.00000.00001.000099.00004.000088.00003.000054.000093.0000

Dividend Frequency

Lastest Dividend

Ex Date Payment Date Dividend Payout per unit
N.A

Portfolio Data

Total Number of Holdings: 132

Number of Bond Holdings: 0

Number of Equity Holdings: 130

Total Market Value: 98,484,016

Portfolio Composition

Top 10 Holdings

% Portfolio Weight Shares Owned Shares Changed Market Value
1ACADIA Pharmaceuticals Inc4.9580205,37008,717,956
2United Therapeutics Corp4.358485,02007,663,703
3Mirati Therapeutics Inc4.215876,22507,412,881
4MorphoSys AG ADR3.9422246,85706,931,745
5Allakos Inc3.736793,86306,570,410
6Immunomedics Inc3.6525372,30906,422,330
7FibroGen Inc3.5492168,62406,240,774
8Alkermes PLC3.5017304,96406,157,223
9Global Blood Therapeutics Inc3.2780116,42005,763,954
10Emergent BioSolutions Inc3.212599,87305,648,817

Country Exposure

Regional Exposure

America

Greater Europe

Greater Asia

Market Classification

Market Capitalization

Size% of portfolio
Giant0.00
Large0.00
Medium3.86
Small46.11
Micro51.66

Equity Style Box Breakdown

000Large
000Mid
000Small
ValueBlendGrowth

Value Measures

Price/Prospective Earnings*

28.9152

Price/Book*

2.0640

Price/Sales*

2.0200

Price/Cash Flow*

12.5976

Dividend Yield*

0.0000

Growth Measures

Long-Term Earnings

5.0772

Historical Earnings

15.5359

Sales Growth

17.3894

Cash-Flow Growth

6.2563

Book-Value Growth

-8.9596

*Forward-looking based on historical data.

Equity Sector

Number of Bond Holdings

0

Bond Statitics

DetailValue
Average Effective Duration0
Average Effective Maturity (Years)*0
Average Credit Quality0
Average Weighted Coupon*0
Average Weighted Price*0

Bond Style Box Breakdown

000HighQuality
000Med
000Low
LtdModExt
Interest-Rate Sensitivity

Credit Quality

Type% Bonds
N.A

Bond Sector

Type
% Bonds

Bond Maturity

% Bonds
N.A

Data Source: Morningstar

© 2019 Morningstar. All Rights Reserved. The information, data, analyses and opinions (“Information”) contained herein:

(1) include the proprietary information of Morningstar and Morningstar’s third party licensors;
(2) may not be copied or redistributed except as specifically authorised;
(3) do not constitute investment advice;
(4) are provided solely for informational purposes;
(5) are not warranted to be complete, accurate or timely; and
(6) may be drawn from fund data published on various dates.

Morningstar and Phillip Securities Pte Ltd are not responsible for any trading decisions, damages or other losses related to the Information or its use. Please verify all of the Information before using it and don’t make any investment decision except upon the advice of a professional financial adviser. Past performance is no guarantee of future results. The value and income derived from investments may go down as well as up.

For the most up-to-date fund’s data and information, a copy of the fund factsheet, information or prospectus may be obtained from the respective ETF issuer.